MedTrace Logo

Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer

NCT00222144 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2012-08-07

No results posted yet for this study

Summary

The primary goal of this study is to determine the effects of the combination of Gleevec and Taxotere in lung cancer in terms of control and reduction of the cancer size. The study will also test lung cancer to see if the presence of certain protein called receptor for platelet derived growth factor can influence the effect of the treatment.

Conditions

Interventions

DRUG

Gleevec and Taxotere

Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Kansas Masonic Cancer Research Institute

    collaborator UNKNOWN

  • University of Kansas

    lead OTHER

Principal Investigators

  • Chao H Huang, MD · University of Kansas Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00222144 on ClinicalTrials.gov